{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:46:48Z","timestamp":1789501608527,"version":"build-2803163510"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed. The results obtained through the meta-analysis showed a risk of serious adverse events after yellow fever vaccination three times higher for the elderly when compared to the non-elderly population and five times higher for persons &gt; 70 years. In relation to adverse event types, viscerotropic disease associated with the yellow fever vaccine had a risk that was six times higher when compared to the population &lt; 60 years. The evidence found supports that the vaccine indication in individuals &gt; 60 years of age should be based on a careful analysis of individual benefit-risk assessments. The results found suggest a higher risk of events for individuals &gt; 70 years, especially for viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this age group.<\/jats:p>","DOI":"10.3390\/vaccines10050711","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:21:25Z","timestamp":1651652485000},"page":"711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0991","authenticated-orcid":false,"given":"Ariane de Jesus Lopes","family":"de Abreu","sequence":"first","affiliation":[{"name":"Instituto Nacional de Cardiologia, Rio de Janeiro 22240-006, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Roberto","family":"Cavalcante","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Wigg","family":"de Ara\u00fajo Lagos","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cardiologia, Rio de Janeiro 22240-006, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1480-2453","authenticated-orcid":false,"given":"Ros\u00e2ngela","family":"Caetano","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-007X","authenticated-orcid":false,"given":"Jos\u00e9 Ueleres","family":"Braga","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil"},{"name":"Escola Nacional de Sa\u00fade Publica Sergio Arouca-FIOCRUZ, Rio de Janeiro 21041-21, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, November 07). Yellow Fever, Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/yellow-fever."},{"key":"ref_2","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil (2021, November 07). Manual de Vigil\u00e2ncia Epidemiol\u00f3gica de Eventos Adversos P\u00f3s-Vacina\u00e7\u00e3o. Bras\u00edlia, Available online: www.saude.gov.br\/bvs."},{"key":"ref_3","unstructured":"World Health Orgnization (2021, November 07). Global Manual on Surveillance of Adverse Events Following Immunization, Available online: www.who.int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jtm.12070","article-title":"Safety of the Yellow Fever Vaccine: A Retrospective Study","volume":"20","author":"Nordin","year":"2013","journal-title":"J. Travel Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.it.2009.05.002","article-title":"Vaccination in the elderly: An immunological perspective","volume":"30","author":"Chen","year":"2009","journal-title":"Trends Immunol."},{"key":"ref_7","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil (2021, November 07). Febre Amarela, Available online: https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/f\/febre-amarela."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow fever control: Current epidemiology and vaccination strategies","volume":"6","author":"Chen","year":"2020","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Klitting, R., Gould, E.A., Paupy, C., and de Lamballerie, X. (2018). What Does the Future Hold for Yellow Fever Virus? (I). Genes, 9.","DOI":"10.20944\/preprints201805.0099.v1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.aau8225","article-title":"The reemergence of yellow fever","volume":"361","author":"Barrett","year":"2018","journal-title":"Science"},{"key":"ref_11","unstructured":"World Health Organization (2021, November 07). Yellow Fever: Latest Outbreak News, Available online: https:\/\/www.who.int\/emergencies\/emergency-events\/item\/yellow-fever."},{"key":"ref_12","unstructured":"World Health Organization (2021, November 07). World Report on Ageing and Health, Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/186463."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1590\/1809-98232016019.150140","article-title":"Population aging in Brazil: Current and future social challenges and consequences","volume":"19","year":"2016","journal-title":"Rev. Bras. Geriatr. Gerontol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/hv.22714","article-title":"Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more","volume":"9","author":"Miyaji","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2013.09.030","article-title":"Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: A systematic review","volume":"31","author":"Rafferty","year":"2013","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taw012","article-title":"Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: Questionnaire survey in Japan over a 1-year period","volume":"23","author":"Tanizaki","year":"2016","journal-title":"J. Travel Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms group PRISMA harms checklist: Improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_23","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil (2021, December 23). Diretrizes Metodol\u00f3gicas Sistema GRADE-Manual de Gradua\u00e7\u00e3o da Qualidade da Evid\u00eancia e For\u00e7a de Recomenda\u00e7\u00e3o Para Tomada de Decis\u00e3o em Sa\u00fade. Bras\u00edlia, Available online: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/diretrizes_metodologicas_sistema_grade.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(97)08468-7","article-title":"Summing up evidence: One answer is not always enough","volume":"351","author":"Lau","year":"1998","journal-title":"Lancet"},{"key":"ref_26","unstructured":"Center for Diseases Control and Prevention (2002). Adverse Events Associated with 17D-Derived Yellow Fever Vaccination\u2014United States, 2001\u20132002. Morb Mortal Wkly Rep., 51, 989\u2013993. Available online: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5144a1.htm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1399-3062.2011.00686.x","article-title":"Yellow fever vaccination in organ transplanted patients: Is it safe? A multicenter study","volume":"14","author":"Azevedo","year":"2011","journal-title":"Transpl. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune Response during Adverse Events after 17D-Derived Yellow Fever Vaccination in Europe","volume":"197","author":"Bae","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","article-title":"Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010","volume":"31","author":"Breugelmans","year":"2013","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril\u00ae: A 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S0037-86822009000100006","article-title":"Vacina\u00e7\u00e3o contra febre amarela em pacientes com diagn\u00f3sticos de doen\u00e7as reum\u00e1ticas, em uso de imunossupressores","volume":"42","author":"Oliveira","year":"2009","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_32","unstructured":"Lawrence, G.L., Burgess, M.A., and Kass, R.B. (2021, November 07). Age-Related Risk of Adverse Events Following Yellow Fever Vaccination in Australia, Available online: https:\/\/www1.health.gov.au\/internet\/main\/publishing.nsf\/Content\/cda-pubs-cdi-2004-cdi2802-htm-cdi2802o.htm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J. Travel Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1016\/j.vaccine.2014.05.003","article-title":"Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil","volume":"32","author":"Martins","year":"2014","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bjid.2018.10.125","article-title":"Seguran\u00e7a da Vacina Contra Febre Amarela em Idosos. Registro da Experi\u00eancia em um Centro de Refer\u00eancia Para Idosos na Baixada Santista","volume":"22","author":"Ujo","year":"2018","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","article-title":"Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases","volume":"25","author":"McMahon","year":"2007","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.vaccine.2014.01.015","article-title":"Yellow fever vaccine-associated adverse events following extensive immunization in Argentina","volume":"32","author":"Biscayart","year":"2014","journal-title":"Vaccine"},{"key":"ref_41","first-page":"e2018331","article-title":"Fatores associados \u00e0 gravidade dos eventos adversos p\u00f3s-vacina\u00e7\u00e3o contra a febre amarela durante o maior surto da doen\u00e7a registrado no Brasil, 2016\u20132017","volume":"29","author":"Lucena","year":"2020","journal-title":"Epidemiol. Servi\u00e7os Sa\u00fade"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.26633\/RPSP.2018.75","article-title":"Yellow fever vaccine and risk of developing serious adverse events: A systematic review","volume":"42","author":"Porudominsky","year":"2018","journal-title":"Rev. Panam. Salud P\u00fablica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tmaid.2015.10.001","article-title":"The elderly, the young and the pregnant traveler\u2014A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination","volume":"13","author":"Jaeger","year":"2015","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5123\/S1679-49742017000300018","article-title":"Risco de reintrodu\u00e7\u00e3o da febre amarela urbana no Brasil","volume":"26","author":"Cavalcante","year":"2017","journal-title":"Epidemiol. Servi\u00e7os Sa\u00fade"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1080\/21645515.2015.1022700","article-title":"Serious adverse events associated with yellow fever vaccine","volume":"11","author":"Martins","year":"2015","journal-title":"Hum. Vaccines Immunother."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:04:56Z","timestamp":1760137496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/5\/711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["vaccines10050711"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10050711","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.23.22272849","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]}}}